Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
A striking example is the human epidermal growth factor receptor 2 (HER2) space, 4 where Kadcyla (ado?trastuzumab tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. Chemical Science.
Let's personalize your content